Australian therapy aimed at halting MND progression and restoring function advances to national Phase 2 trial

An Australian biotechnology company, NuNerve, is advancing its therapy NUN-004 into a Phase 2 clinical trial for motor neurone disease (MND). The therapy aims to protect motor neurons and support the repair of neural connections, potentially reversing disease progression.
Why it matters
Represents a significant scientific advancement in treating neurodegenerative diseases, moving beyond symptom management toward potential functional restoration.
Video interviews, overlay and photos here
BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- An Australian-developed therapy aimed at halting the progression of motor neurone disease (MND) and restoring function by supporting the repair of damaged neural connections is advancing into a national Phase 2 clinical trial.
The 75-participant trial follows encouraging early signs of disease stabilisation and functional improvement in a Phase 1/1b study of NUN-004, the lead investigational therapy from Queensland-based clinical-stage CNS (central nervous system) biotechnology company, NuNerve.
Motor neurone disease (MND), also known as amyotrophic lateral sclerosis (ALS) , is a progressive neurological condition that affects the nerve cells in the brain and spinal cord responsible for movement. As these motor neurons deteriorate and die, the brain can no longer send signals to the muscles, leading to muscle weakness, wasting, and loss of function over time.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in